Thu, May 8, 11:10 AM (8 days ago)
**Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $50.0 million, up 5% from Q1 2024 ($47.5 million). - **Net Loss:** $29.5 million, significantly higher than Q1 2024's $4.1 million. - **Cash & Equivalents:** $111.8 million, down from $102.3 million in Q4 2024. - **Marketable Securities:** $229.1 million, down from $272.3 million in Q4 2024. **Product Performance:** - **Fanapt®:** Net sales up 14% to $23.5 million, driven by increased volume. - **HETLIOZ®:** Net sales up 4% to $20.9 million, with increased price but decreased volume. - **PONVORY®:** Net sales down 18% to $5.6 million, due to decreased volume. **Operational Highlights:** - **Fanapt®:** Approved for bipolar I disorder in Q2 2024, commercial launch initiated in Q3 2024. - **HETLIOZ®:** Maintained market share despite generic competition. - **PONVORY®:** Commercial launch initiated in Q3 2024, new patient prescriptions reached a record high in April 2025. **Regulatory & Clinical Development:** - **Tradipitant:** NDA for motion sickness accepted by FDA with a PDUFA target date of December 30, 2025. - **Bysanti™:** NDA for bipolar I disorder and schizophrenia accepted by FDA with a PDUFA target date of February 21, 2026. - **Imsidolimab:** BLA for GPP expected to be submitted to the FDA in 2025. **Cash Flow:** - **Operating Activities:** $33.1 million used, down from $7.6 million provided in Q1 2024. - **Investing Activities:** $43.9 million provided, up from $18.2 million used in Q1 2024. - **Financing Activities:** $1.3 million used, no financing cash flows in Q1 2024. **Liquidity & Capital Resources:** - **Total Cash & Equivalents:** $340.9 million, down from $374.6 million in Q4 2024. - **Future Cash Requirements:** Dependent on revenue generation, commercial activities, and clinical development. **Uncertainties & Future Operations:** - **Revenue Variability:** Potential decline due to Medicare Part D program redesign and generic competition. - **Legal Matters:** Ongoing lawsuits related to HETLIOZ® and other products. - **Future Financing:** May require additional capital through debt, equity, or partnerships. **Ticker:** VNDA